- Home
- CRWD vs GILD Comparison
CRWD vs GILD Comparison
Compare CRWD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRWD
- GILD
- Stock Information
- Founded
- CRWD 2011
- GILD 1987
- Country
- CRWD United States
- GILD United States
- Employees
- CRWD N/A
- GILD N/A
- Industry
- CRWD EDP Services
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRWD Technology
- GILD Health Care
- Exchange
- CRWD Nasdaq
- GILD Nasdaq
- Market Cap
- CRWD 103.8B
- GILD 119.7B
- IPO Year
- CRWD 2019
- GILD 1992
- Fundamental
- Price
- CRWD $406.68
- GILD $109.95
- Analyst Decision
- CRWD Buy
- GILD Buy
- Analyst Count
- CRWD 44
- GILD 27
- Target Price
- CRWD $383.43
- GILD $101.88
- AVG Volume (30 Days)
- CRWD 3.4M
- GILD 7.9M
- Earning Date
- CRWD 03-04-2025
- GILD 02-11-2025
- Dividend Yield
- CRWD N/A
- GILD 2.87%
- EPS Growth
- CRWD N/A
- GILD N/A
- EPS
- CRWD 0.51
- GILD 0.38
- Revenue
- CRWD $3,740,421,000.00
- GILD $28,754,000,000.00
- Revenue This Year
- CRWD $31.14
- GILD $1.72
- Revenue Next Year
- CRWD $21.26
- GILD $3.51
- P/E Ratio
- CRWD $790.54
- GILD $289.34
- Revenue Growth
- CRWD 31.35
- GILD 6.04
- 52 Week Low
- CRWD $200.81
- GILD $62.07
- 52 Week High
- CRWD $455.59
- GILD $111.03
- Technical
- Relative Strength Index (RSI)
- CRWD 48.29
- GILD 75.82
- Support Level
- CRWD $424.08
- GILD $94.56
- Resistance Level
- CRWD $455.59
- GILD $106.69
- Average True Range (ATR)
- CRWD 14.34
- GILD 2.29
- MACD
- CRWD -1.61
- GILD 1.15
- Stochastic Oscillator
- CRWD 31.45
- GILD 93.47
About CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).